How should insomnia be managed in a 78-year-old female with newly diagnosed Alzheimer’s disease who is taking escitalopram (Lexapro) 20 mg daily and trazodone 20 mg at bedtime?

Management of Persistent Insomnia in a 78-Year-Old with Alzheimer's Disease

Increase the trazodone dose from 20 mg to 50 mg at bedtime, as this is the evidence-based dose shown to improve sleep in Alzheimer's patients, while simultaneously implementing cognitive-behavioral therapy for insomnia (CBT-I) and sleep hygiene measures. 1

Rationale for Dose Adjustment

The current trazodone dose of 20 mg is subtherapeutic. The FDA-approved dosing for trazodone starts at 150 mg/day for depression 2, but for sleep disorders in older adults with dementia, 50 mg at bedtime is the established effective dose. A randomized, double-blind, placebo-controlled trial specifically in Alzheimer's patients demonstrated that trazodone 50 mg significantly increased total nocturnal sleep time by 42.5 minutes and improved sleep efficiency by 8.5 percentage points, with no adverse effects on cognition or daytime functioning 1. This is the highest quality evidence available for pharmacologic treatment of insomnia in this specific population.

Why Not Other Options

Melatonin should NOT be added or substituted - A Cochrane systematic review found no evidence that melatonin (either immediate or slow-release) improved any major sleep outcome in patients with moderate-to-severe Alzheimer's disease 3. The evidence shows no benefit for total nocturnal sleep time, sleep efficiency, or daytime sleep.

Benzodiazepines and Z-drugs (zolpidem, zopiclone) should be avoided in this 78-year-old patient. Guidelines explicitly state that older adults are at greater risk for adverse effects including falls, cognitive impairment, and dependence 4. The 2005 NIH State-of-Science Conference concluded that risks outweigh benefits for most sedative-hypnotics in elderly patients 4.

The escitalopram 20 mg is appropriate to continue - while SSRIs don't directly treat insomnia and recent evidence shows they don't reduce agitation in AD 5, discontinuing it abruptly could cause withdrawal symptoms. However, be aware that SSRIs are associated with increased fall risk 5.

Non-Pharmacologic Interventions (Essential First-Line)

Guidelines emphasize that behavioral therapy should be implemented whenever possible 4. CBT-I has robust evidence in older adults and should be combined with medication for optimal outcomes 4, 6. Specific interventions include:

• Sleep hygiene education: Fixed wake time regardless of sleep obtained, avoid daytime napping after 2 PM (limit to 30 minutes if needed), bedroom only for sleep
• Stimulus control: Leave bedroom if unable to fall asleep within 20 minutes, return only when sleepy
• Environmental modifications: Avoid caffeine, nicotine, alcohol; no heavy exercise within 2 hours of bedtime
• Bright light therapy in the morning may augment treatment effects 4

Implementation Algorithm

1. Immediately increase trazodone to 50 mg at bedtime (taken shortly after a light snack per FDA guidance 2)

2. Implement sleep hygiene measures concurrently - this is not optional

3. Monitor for 2 weeks for:

   • Sleep improvement (total sleep time, nighttime awakenings)
   • Daytime drowsiness (if occurs, give entire dose at bedtime - already doing this)
   • Falls risk (particularly given concurrent SSRI use)
   • Cognitive function (trazodone at 50 mg showed no cognitive decline in trials 1)

4. If inadequate response after 2 weeks at 50 mg, consider:

   • Reassess for underlying causes (pain, sleep apnea, restless legs, medication side effects)
   • Refer for formal CBT-I if not already implemented
   • Dual orexin receptor antagonists (suvorexant, lemborexant) are newer options with evidence in AD 7, 8, though more expensive

Critical Safety Considerations

Fall risk is elevated - Both escitalopram and trazodone can increase fall risk, particularly in combination 5. Ensure home safety evaluation and consider physical therapy for gait/balance assessment.

Avoid adding quetiapine - Despite common off-label use for insomnia in older adults, recent 2025 data shows low-dose quetiapine significantly increases mortality (HR 3.1), dementia progression (HR 8.1), and falls (HR 2.8) compared to trazodone 9.

Monitor for serotonin syndrome - The combination of escitalopram and trazodone theoretically increases risk, though trazodone 50 mg is a low dose. Watch for agitation, confusion, tremor, or autonomic instability 10.

Gradual discontinuation if stopping - Both escitalopram and trazodone require gradual dose reduction to avoid discontinuation syndrome 2, 10.

What NOT to Do

• Do not continue subtherapeutic trazodone 20 mg expecting improvement
• Do not add benzodiazepines or Z-drugs given age and dementia
• Do not add melatonin (no evidence of benefit in AD)
• Do not use antihistamines (anticholinergic burden worsens cognition)
• Do not add antipsychotics for insomnia alone (increased mortality risk)

The evidence strongly supports optimizing trazodone to the proven effective dose of 50 mg while ensuring non-pharmacologic interventions are properly implemented 1, 3.